Pharma BD Deal Intelligence
Bristol Myers deepens ties with Dragonfly Therapeutics aiming for immunotherapy boost with IL-12 and TriNKET combination approaches
Bristol Myers Squibb pens $475M Dragonfly pact for IL-12 program including extended half-life cytokine DF6002 for solid tumor treatment
Dragonfly announced it now owns all rights to develop DF6002, its IL-12 cytokine immunotherapy (Phase 1, monotherapy and with nivolumab); rights reverted from…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
BMS licensed Dragonfly's IL-12 program (DF6002/BMS-986415) for $475M upfront and expanded its TriNKET NK-cell-engager collaboration. In Feb 2023, BMS returned all rights to the IL-12 asset DF6002 (then in Phase 1) to Dragonfly, ending the headline component of this deal; the upfront was retained by Dragonfly. The broader BMS-Dragonfly TriNKET relationship continued, with BMS holding six licensed TriNKET candidates (two in clinic) and a separate Jan 2023 neuroinflammation TriNKET license.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Dragonfly Therapeutics Inc. (this deal) | 2020 | $475M | 55 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2020 deals · Bristol-Myers Squibb Company deals · Oncology deals